OBER 

July 16,2012 

VIA MESSENGER 

Mr. Donald S. Clark 

Secretary 

KALER 

Attorneys at Law 

Federal Trade Commission 

600 Pennsylvania Avenue, N.W. 

Room 135-H 

Washington, DC 20580 

Dear Mr. Clark: 

Dber, Kaler, Grimes & Shriver 

A Professional Corporation 

1401 H Street, NW, Suite 500 

Washington, DC 20005 

202.408.8400 Main 

202.408.0640 Fax 

www.ober.com 

E. John Steren 

ejsteren@ober.com 

202.326.5017 I Fax: 202.336.5217 

Offices In 

Maryland 

Washington, D.C. 

Virginia 

Pursuant to Federal Trade Commission Procedure Rules 1.1 through 1.4, 16 C.F.R. §§ 

1.1-1.4 , the Generic Pharmaceutical Association, Inc. ("GPhA") requests an advisory opinion 

addressing the Commission's enforcement intentions regarding a voluntary program referred to 

as the Accelerated Recovery Initiative ("ARl"). The ARl is designed to obtain and provide to 

the United States Food and Drug Administration ("FDA") key information that will enable the 

FDA's Drug Shortage Program ("DSP") more efficiently and effectively to accelerate the 

recovery of critical drugs in short supply. As explained in further detail below, GPhA expects 

that, with the key information provided by ARl, the FDA will be better positioned to prevent or 

eliminate shortages of critical, medically necessary drugs, thus helping patients/consumers 

receive the drugs they need, when they need them. ARI proposes to accomplish its mission by 

having a third-party vendor, IMS Health Incorporated ("IMS"), gather and provide to the FDA 

supply and expected product release information from manufacturers, thereby giving the FDA 

not only a better understanding of current and future market conditions for drugs in short supply 

but also an enhanced ability to work with manufacturers to expand the supply of these critical 

medications to patients in need. As competitively sensitive information collected by IMS will 

be available only to the FDA, and not to manufacturers or other stakeholders, this program is not 

expected to have any effect on product pricing or otherwise facilitate any unlawful agreements 

between or among its participants. Furthermore, the FDA has publicly stated its support for ARI 

announcing, through its spokeswoman Shelly Burgess, that the program would provide "exactly 

the data FDA needs .... " 

See Generics Industry's Drug Shortage Plan wins FDA Support, Law 360, April 19, 2012, 

http://www.law360.com/articies/331913/print?section=lifesciences (attached hereto as Exhibit 1). 
Donald S. Clark 

July 16,2012 

Page 2 

I. Background on Critical Drug Shortages. 

OBER KALER 

It is an unfortunate fact that certain prescription drugs face sporadic and critical supply 

shortages? As noted by the United States Department of Health and Human Services ("HHS"), 

medically necessary,3 injectable drugs in particular have been disproportionally affected by 

"class-wide shortages.,,4 In fact, recent studies by HHS and IMS Health Incorporated indicate 

that over eighty percent (80%) of the drugs on the FDA Drug Shortage List ("DSL") (described 

at pg. 3 below) are generic injectable drugs, used by acute care patients being treated by 

providers in hospitals and out-patient facilities, and that as much as fifty percent (50%) of all 

generic, injectable drugs used in the United States are on the FDA Drug Shortage List.5 

According to HHS, current drug shortages appear to be a consequence of a substantial 

expansion in the demand that has occurred over a short period of time, without a corresponding 

expansion in manufacturing capacity. The expansion in product demand and quantity, in tum, 

stems from both an increase in the overall volume of drugs used and an unusually high rate of 

patent expirations that began in 2008 and has continued through 2010. 6 

Furthermore, HHS has indicated that current shortages may not be completely resolved 

until new supply sources come on line as the manufacturing industry increases its capacity.7 

However, the regulatory framework governing the industry delays by several years the ability of 

new suppliers to enter or the ability of existing suppliers to add production capacity. While the 

FDA continues to respond to the ever increasing drug shortages through, among other things, its 

Drug Shortage Program, and moving when possible to expedite its approval process for 

alternative supplies - see for example its approval of the temporary importation of certain cancer 

treatments as a case in point8 - additional actions are needed to stem the increasing tide of drug 

shortages. The HHS study concludes by recommending, among other things, that immediate 

responses to the problem of shortages should focus on increasing the extent of supply 

A "drug shortage," as defmed by the FDA, is present when "total supply of all clinically interchangeable 

versions of an FDA-regulated drug is inadequate to meet the current or projected demand at the user level." See 

Economic Analysis of the Causes of Drug Shortages, ASPE Issue Brief dated October 2011 at note 1 (attached 

hereto as Exhibit 2). 

A "medically necessary" drug, as defmed by the FDA, is one "used to treat or prevent a serious medical 

condition for which there is no other alternative drug, available in adequate supply that is judged by medical staff to 

be an adequate substitute." [d. Exhibit 2 at note 1. 

See Exhibit 2 at pg. 1. 

See Drug Shortages: A closer look at products, suppliers and volume volatility, November 2011, IMS 

Institute for Healthcare Informatics (attached hereto as Exhibit 3). 

See Exhibit 2 at pg. 1. 

See Exhibit 2 at pg. 2. 

See Jennifer C. Dooren, Suppliers for Cancer Drugs Get Approval, Wall St. J., Feb. 22, 2012, at B3. 
Donald S. Clark 

July 16, 2012 

Page 3 

OBER KALER 

responsiveness in the market. ARI is positioned to assist in facilitating this goal by putting key 

information in the hands of the FDA. 

II. The FDA Drug Shortage Program and Drug Shortage List. 

As a result of the increasing number and complexity of drug shortages, the FDA, through 

its Center for Drug Evaluation and Research ("CDER") located in Rockville, Maryland, 

developed the Drug Shortage Program ("DSP"). The purpose of the DSP is to ensure the 

availability of safe and effective drugs to the American public by, among other means, 

monitoring critical drugs and medical countermeasures, including those in the Strategic National 

Stockpile, to ensure availability for emergency situations.9 The DSP also serves as a liaison with 

other FDA centers, other government organizations including the Center for Disease Control and 

the Department of Defense, and private industry. 

The DSP uses publicly available information to notify suppliers and the public of present 

and upcoming shortages in an effort to mitigate or stem the shortage. The DSP makes use of the 

mandatory disclosures by manufacturers that must report the discontinuation of production of 

any sole-sourced production of a medically necessary product. See Section 506[ c] of the 

Federal, Food, Drug, and Cosmetic Act 21 U.S.C. § 356c. However, all of the remaining 

information used by the DSP is supplied on a voluntary basis. 1o 

The DSP posts this information on the FDA publicly available web site in the form of a 

list (the "DSL"), which currently includes the name of the drug, the formulation, the 

manufacturer, the anticipated time frame for the agent's availability, phone numbers and other 

important communications from the manufacturer relating to the product shortage. 11 ARI 

incorporates information from this list as a starting point, and seeks to enhance the FDA's ability 

to arrange production based solutions to mitigate or resolve the shortage at issue. 

9 CEDR Manual of Policies and Procedures ("MAPP"), dated 02/03/2012, at pg 2 (attached hereto as Exhibit 

4). 

10 Under section 1001 of the recently enacted FDA Safety and Innovation Act, a drug manufacturer will now 

also be required to notify the Secretary of any expected "interruption ... that is likely to lead to a meaningful 

disruption in the supply of that drug ... and the reason for such ... interruption" six months prior to the expected 

interruption or as soon as practical. 

11 A copy of the most recent DSL is attached as Exhibit 5. It should be noted that section 1004 of the FDA 

Safety and Innovation Act now mandates that the Drug Shortage List contain the following information: 1) The 

name ofthe drug and its National Drug Code number; 2) The name of each manufacturer of the drug; 3) The reason 

for the shortage selecting from the following categories: A) Requirements related to complying with good 

manufacturing practices; B) Regulatory delay; C) Shortage of active ingredient; D) Shortage of an active ingredient 

compound; E) Discontinuation of the manufacture of the drug; F) Delay in shipping of the drug; G) Demand 

increase for the drug; and 4) The estimated duration of the shortage. 
OBER KALER 

Donald S. Clark 

July 16,2012 

Page 4 

III. GPhA and ARl. 

GPhA is a trade association that represents manufacturers and distributors of finished 

dose generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals 

and suppliers of other goods and services to the generic drug industry. GPhA was founded in 

2001, following the merger ofthree industry trade organizations: the Generic Pharmaceutical 

Industry Association, the National Association of Pharmaceutical Manufacturers, and the 

National Pharmaceutical Alliance. 12 GPhA is a tax-exempt business league under Section 

501 (c)( 6) of the Internal Revenue Code of 1986, as amended. 

GPhA is run by a full-time staff and Executive team lead by its President and Chief 

Executive Officer, Ralph G. Neas.13 The Board of Directors consists of 15 industry 

representatives. 14 Regular, or voting, membership in GPhA is open to any corporation, 

partnership or other legal entity that derives more than fifty percent (50%) of its net revenues in 

the United States from the commercialization, manufacture, sale and/or marketing of finished 

dose pharmaceutical products that are (1) products described in Abbreviated New Drug 

Applications filed with the U.S. Food & Drug Administration; (2) products sold as authorized 

generic drugs in the U.S., (3) biosimilar and biogeneric products, as described in Section 351(k) 

of the Public Health Service Act, as amended; and (4) Drug Efficacy Study Implementation 

(DESI) products. IS 

As members of the public who also are affected by shortages, the generic pharmaceutical 

industry is devoted to working with all stakeholders to minimize current shortages and mitigate 

factors that could contribute to future shortages. In accordance with this mission, GPhA has 

identified the following objectives for ARI: 

12 

\3 

14 

• Collect and aggregate, via an independent third party under terms of strict 

confidentiality and with appropriate safeguards (as described further below), 

current and future production information for those products identified on the 

FDA Drug Shortage List that satisfy the ARI criteria outlined below; 

• Through IMS, work with CDER's Drug Shortage staff to determine current and 

potential supply gaps, with a focus on those products where a shortage is expected 

to last longer than 90 days; and 

• Through IMS, work with CDER's Drug Shortage staff to ensure the FDA's 

connectivity with key market participants in the supply chain of the critical drugs. 

Additional background information relating to GPhA can be found on its website at www.gphaonline.org. 

A listing of GPhA's staffis attached hereto as Exhibit 6. 

A listing of GPhA's Board members is attached hereto as Exhibit 7. 

15 Attached as Exhibit 8 is a current GPhA membership listing. This list identifies both voting ("Regular") 

and non-voting ("Associate") members of GPhA. 
OBER KALER 

Donald S. Clark 

July 16,2012 

Page 5 

Pursuit ofthese objectives will involve IMS' collection and analysis of critical public and 

non-public production related infonnation, and the provision ofthat infonnation and analysis to 

the FDA. Thus, ARI will position IMS to become a clearinghouse of relevant information 

concerning the supply of critical drugs. As described in further detail below, IMS will not 

collect pricing or price-related infonnation, and procedural safeguards will be put in place to 

protect confidential data and prevent the inappropriate uses of the collected infonnation. 

IV. Identification and Retention of an Independent Third Party Manager. 

GPhA identified a number of companies capable of serving as a third party manager 

responsible for the collection of relevant infonnation, and the aggregation and provision of that 

infonnation to the FDA. Each of these companies was interviewed to determine their suitability 

to run ARI and, although several were well qualified, IMS emerged as the candidate best suited 

to supply the needed services. IMS has been providing infonnation solutions to entities in the 

healthcare industry, including pharmaceutical providers, for more than 50 years and already 

tracks over 80% of global phannaceutical sales activity accounting for more than 1.3 million 

products. 16 

GPhA and IMS have signed a preliminary non-disclosure agreement and are currently in 

discussions regarding the operation of ARI. 17 Although ARI will be initiated as a GPhA 

program, ARI may ultimately operate as a stand-alone, non-profit entity. 

IMS is expected, based on its experience and knowledge, to develop the mechanics of the 

program, including the type of infonnation that it needs to collect, the analysis that it will 

conduct, and manner in which the infonnation and analysis will be transmitted by IMS to the 

FDA. As a general overview, ARI, working through IMS, is expected to function as follows: 

16 

17 

1. FDA, in consultation with GPhA, will identify/focus on a subset of medically 

necessary products on the DSL that are expected to be in short supply for more than 

90 days, and provide this list of drugs to IMS 18; 

2. Through available market sources, including information from the DSL, IMS will 

identify and, with the assistance of GPhA, individually contact all of the 

manufacturers of the products identified in the subset above in an effort to sign them 

up to participate in ARI; 

Additional background information relating to IMS can be found on its website at www.imshealth.com. 

A draft of the non-disclosure agreement is attached as Exhibit 9. 

18 Drugs meeting the following criteria are expected to be included in the subset of targeted products: 1) 

currently on the FDA Drug Shortage List; 2) currently listed on the ASHP Drug Shortage List (as no single agent 

can be substituted or no alternative for a particular indication); 3) it is either an ANDA product or a "grandfathered" 

product; 4) it is multi-source (i.e., there are potential alternative suppliers); and 5) having a projected shortage of 

longer than 90 days. In addition, the FDA will have discretion to add products to this list that it believes can benefit 

from ARI if circumstances warrant. 
OBER KALER 

Donald S. Clark 

July 16,2012 

Page 6 

3. Participation in ARI will be memorialized by a Participation and Confidentiality 

Agreement covering the voluntary disclosure of relevant information; 19 

4. Participating manufacturers will be expected to: a) provide IMS with their respective 

90 to 180 day supply schedules/forecasts covering those products identified on the 

ARI list; b) to regularly update, on a monthly basis, the supply schedules provided to 

IMS; c) to provide IMS and the FDA with immediate notice of unanticipated changes 

to the existing supply schedule reflecting potential and/or expected production 

problems not previously disclosed on the DSL or otherwise (these communications 

will occur between IMS and each individual manufacturer, not in collaboration with 

any other manufacturer); 

5. IMS, based on its industry knowledge and information received from manufacturers, 

will be expected to perform a "gap analysis" that analyzes and charts the anticipated 

supply and projected demand of the product and, when possible, note historical 

production levels for all current and former suppliers of the product at issue; 

6. IMS will then transmit this analysis and information to the FDA; and 

7. The FDA is expected to review this analysis transmitted from IMS along with related 

information regarding the drug at issue including time frames for expected approvals 

of additional manufacturers, new capacity, and potential closings of other related 

lines (information the FDA is in possession ot), and then initiate contact with the 

other manufacturers of the drug at issue in an effort to increase production. 

v. Competitive Considerations 

A. Total Market Participation. 

Total participation is key to identifying and understanding the cause of the potential 

shortage, and to finding a solution to prevent or stem the potential shortage, and GPhA seeks 

100% participation in ARI by manufacturers of medically necessary products. 20 Despite the 

19 A draft of the Participation and Confidentiality Agreement and Antitrust Guidelines is attached as Exhibit 

10. 

20 According to HHS, the "[m]anufacture of generic, sterile injectable drugs is a somewhat concentrated 

market with 7 manufacturers making up a large percentage of the market. Most of the production of a given drug is 

by three or fewer manufacturers. Analysis of a sample of 33 generic sterile injectable oncology drugs shows that of 

33 drugs, for 28 at least 90 percent of the total unit sales in 2010 was by 3 or fewer manufacturers. These 

manufacturers each operate a small number of facilities (1-10) at which injectable drugs can be produced. These 

facilities, in tum, each contain several manufacturing lines. A particular drug can be produced on one or more of 

these lines, in runs that may last hours to weeks. The same line may be used for multiple different drugs (produced 

in separate batches), however, certain drugs (including cytotoxic drugs) may only be produced on certain types of 

Jines and in certain types offacilities, so the extent of substitution is limited. Moreover, there are costs in shifting 

from one drug to another on a specific line." See Exhibit 2 at pg. 6. 
Donald S. Clark 

July 16,2012 

Page 7 

OBER KALER 

anticipated level of participation, for the reasons described below, GPhA does not believe ARl 

will result or enable any adverse consequences to competition for these products. 

B. The Exchange of Sensitive Information Will be Limited and Controlled. 

As previously noted, information to be collected by IMS under the auspices of ARl will 

not include price, price related information, or cost information of any kind. However, in order 

for the program to be successful, participants will be asked to voluntarily supply IMS with 

current and projected (up to 180 days) production schedules for certain medically necessary 

drugs already on the DSL. A number of protections/protocols will be established to ensure that 

the confidential nature of this information is preserved. 

1. All participants will be required to enter into a separate confidentiality agreement 

with GPhA and IMS that is intended to safeguard the disclosure of this 

information; 

2. Participants will supply information only to IMS, and not, directly or indirectly, to 

other participants; 

3. IMS will establish appropriate internal protections including firewalls as needed 

to ensure that information received from participating manufacturers is not 

disclosed to other divisions within IMS; 

4. IMS will not disseminate information to any of the participants but instead will 

use the information to help identify manufacturers with capacity to help stem or 

prevent the shortage; 

5. IMS will transmit its analysis and conclusions only to the FDA and allow the 

FDA to communicate directly with manufacturers to determine whether they are 

willing to produce additional quantities of the medically necessary drug to prevent 

or stem the anticipated shortage; and 

6. Reporting from IMS back to GPhA will be limited to the identification of drugs 

under review and will not include any of the competitively sensitive 

production/supply information provided by ARl participants or information about 

products (including the identification of any product) that is not already contained 

in the Drug Shortage List. 

C. The Disclosure of Supply Information Should Not Affect Prices. 

ARI will orchestrate the provision of supply related information to IMS, and 

subsequently to the FDA, that supplements the FDA's existing knowledge regarding drugs 

already in short supply. As the identification of these products is already publicly available on 

the DSL, it is unlikely that additional information relating to supply and capacity to produce the 

drug at issue could be used in a fashion that would have any impact on prices or otherwise result 
Donald S. Clark 

July 16,2012 

Page 8 

OBER KALER 

in an agreement that would have any adverse effect on competition.21 Furthermore, the 

competitively sensitive information gathered by IMS will not be posted, in its raw or analyzed 

form, on the FDA website. 

No price, cost or related information will be collected by IMS. Furthermore, all 

information collected by IMS under the auspices of ARI is subjected to a confidentiality 

agreement and will only be seen and analyzed by IMS and the FDA. Finally, how this 

information gets used, including the ultimate communication with manufacturers seeking 

to stem the drug shortage, is controlled by the FDA. 

IV. Conclusion 

In conclusion, we respectfully submit that the ARI Program is not likely to facilitate any 

sort of anti competitive practice or effect. The benefits to patients are very significant-they will 

have greater access to the drugs they need. 

Pursuant to Federal Trade Commission Procedure Rule lA, 16 C.F.R. § lA, GPhA and 

ARI request that documents attached hereto as exhibits 8 and 9 be treated as confidential under 

Federal Trade Commission Procedure Rule 4.10, 16 C.F.R. § 4.10(a)(2), and § 6(f) of the Federal 

Trade Commission Act, 15 U.S.C. § 46(f). All information to be withheld is competitively 

sensitive information. 

We look forward to feedback from the FTC. Please contact us if there is anything else 

we can provide that would be helpful to your analysis. 

21 The study from HHS, attached hereto as Exhibit 2, gives a succinct explanation of why shortages are a 

feature of the prescription drug market and why a shortage in product generally does not correspond to an increase 

in price. Although we have not performed any additional analysis, we believe that its findings also support the 

conclusion that ARI's efforts to gap short term supply shortages will not affect prices.